^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | sabatolimab (MBG453) (TIM-3 antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SABATOLIMAB PLUS HYPOMETHYLATING AGENTS (HMAS) IN PATIENTS (PTS) WITH HIGH-/VERY HIGH-RISK MYELODYSPLASTIC SYNDROME (HR/VHR-MDS) AND ACUTE MYELOID LEUKEMIA (AML): SUBGROUP ANALYSIS OF A PHASE 1 STUDY
Published date:
05/12/2021
Excerpt:
To explore sabatolimab+HMA safety/tolerability, sabatolimab dose interruption (>7 d delay), reduction…6/7 responders with TP53 mutation had complex karyotype….Sabatolimab+HMA showed favorable tolerability in MDS/AML…
